Mesoporous Nano-Magnesium Oxide for Low-Toxic Drug Loading
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nanodrug carriers, particularly those made from inorganic nanoparticles like gold, silver, copper, and iron oxides, suffer from large toxic side effects and lack uniformity in particle size, which affects their efficacy and safety for drug delivery.
Innovation Solution
The development of mesoporous nano-magnesium oxide with controlled particle size (50-150 nm) and abundant mesopores (2-20 nm) on the surface, optimized through a co-precipitation and calcination process using magnesium chloride hexahydrate and oxalic acid, ensuring minimal toxicity and efficient drug loading.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If traditional inorganic nanoparticles (gold, silver, copper, iron oxides) are used as nanodrug carriers, then stable structure is achieved, but large toxic side effects occur
Solution Approach 1:
The patent changes the material composition parameter from traditional inorganic nanoparticles (gold, silver, copper, iron oxides) to magnesium oxide nanoparticles. This parameter change maintains structural stability while dramatically reducing toxic side effects, as magnesium oxide is biocompatible and can be metabolized by the body into magnesium ions and water.
Solution Approach 2:
The patent employs magnesium oxide nanoparticles that are designed to be transient and metabolizable rather than permanent. These nanoparticles degrade into harmless magnesium ions and water after delivering their drug payload, eliminating long-term accumulation and chronic toxicity issues associated with traditional inorganic carriers.
2Object-generated harmful factors
If nano-magnesium oxide is used as a drug carrier, then minimal toxic side effects are achieved, but large particle size and size non-uniformity occur
Solution Approach 1:
The patent uses surfactants and dispersants in the synthesis process to pre-establish uniform particle formation conditions before calcination. These additives prevent aggregation during particle formation and ensure consistent nucleation, resulting in narrow particle size distributions centered around the target 50 nm diameter.
Solution Approach 2:
The patent optimizes multiple synthesis parameters including precursor concentration, mixing rate, temperature, and calcination conditions to achieve precise control over particle size. By carefully adjusting these parameters, the patent produces nanoparticles with diameters predominantly between 20-100 nm, with most particles around 50 nm.
3Quantity of substance
If mesoporous structure is introduced to nano-magnesium oxide, then drug loading capacity is improved, but particle size control becomes more difficult
Solution Approach 1:
The patent introduces a mesoporous structure into the magnesium oxide nanoparticles with pore diameters of 2-20 nm. This porous architecture dramatically increases the surface area and internal volume available for drug loading, allowing high drug capacity while maintaining the external particle size of 50 nm through controlled formation during calcination.
Solution Approach 2:
The patent creates a composite structure combining the magnesium oxide matrix with an organized mesoporous network. This composite architecture integrates the structural stability of magnesium oxide with the high drug-loading capacity of porous materials, achieving both small particle size and high drug capacity simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mesoporous nano-magnesium oxide provides enhanced drug delivery efficiency, stability in the body, and rapid dissolution in acidic tumor environments, reducing toxic side effects and improving drug utilization.
Implementation Method 1
the magnesium oxalate hydrate intermediate is calcined to produce magnesium oxide with micro-nano structures
Implementation Method 2
MgC2O4·nH2O, and the magnesium oxalate hydrate intermediate is calcined to produce magnesium oxide
Implementation Method 3
the mesoporous nano-magnesium oxide can respond sensitively to a pH value, can be quickly dissolved in an acidic environment within a tumor
Implementation Method 4
MgCO3 is mixed with oxalic acid to produce a magnesium oxalate hydrate intermediate
Data Source
AI summary
A mesoporous nano-magnesium oxide for drug loading and a preparation method thereof are provided. The mesoporous nano-magnesium oxide particle has a particle size of 50 nm to 150 nm, and includes abundant mesoporous structures with a pore size of 2 nm to 20 nm. A surface of the particle has a positive potential in absolute ethanol, with a Zeta potential distribution of 10 mV to 100 mV. The preparation method includes: preparing a mixture of magnesium oxalate and CTAB as a precursor; adding the precursor to a quartz crucible, and placing the quartz crucible in a muffle furnace; calcining at 200℃ for 1 h to make the CTAB in the mixture completely decomposed to produce pure magnesium oxalate; and heating to 530°C, and calcining for 1 h to 6 h to make the magnesium oxalate fully decomposed to produce the nano-magnesium oxide microparticle.